ARS Pharmaceuticals Reports the EC’s Approval of Eurneffy (Adrenaline Nasal Spray) to Treat Type I Allergic Reactions
Shots:
-
Following the US FDA approval, the EC has approved Eurneffy (2mg) for type I allergic reactions (anaphylaxis) in adults & children (≥30kg). It will be available in Q4’24 through a pharmaceutical company
-
The approval was supported by the results from a study, involving ~1200 administrations among >700 subjects, along with studies and peer-reviewed literature supporting these results
-
The study assessed PK/PD of Eureffy (2mg) under various conditions such as single and repeat dosing, self-administration, pediatric dosing & in nasal conditions like congestion and rhinorrhea due to allergens or infections like cold/flu
Ref: ARS Pharmaceuticals | Image: ARS Pharmaceuticals
Related News:- ARS Pharmaceuticals’ neffy (Epinephrine Nasal Spray) Gains the US FDA’s Approval to Treat Type I Allergic Reactions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
